Related Experiment Video
Updated: Oct 10, 2025
Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression
Han Seok Koh1, SangJoon Lee2, Hyo Jin Lee1
1BIORCHESTRA Co., Ltd., 17, Techno 4-ro, Yuseong-gu, Daejeon 34013, Korea.
Abstract:
Alzheimer's disease (AD) is a form of dementia characterized by progressive memory decline and cognitive dysfunction. With only one FDA-approved therapy, effective treatment strategies for AD are urgently needed. In this study, we found that microRNA-485-3p (miR-485-3p) was overexpressed in the brain tissues, cerebrospinal fluid, and plasma of patients with AD, and its antisense oligonucleotide (ASO) reduced Aβ plaque accumulation, tau pathology development, neuroinflammation, and cognitive decline in a transgenic mouse model of AD. Mechanistically, miR-485-3p ASO enhanced Aβ clearance via CD36-mediated phagocytosis of Aβ in vitro and in vivo. Furthermore, miR-485-3p ASO administration reduced apoptosis, thereby effectively decreasing truncated tau levels. Moreover, miR-485-3p ASO treatment reduced secretion of proinflammatory cytokines, including IL-1β and TNF-α, and eventually relieved cognitive impairment. Collectively, our findings suggest that miR-485-3p is a useful biomarker of the inflammatory pathophysiology of AD and that miR-485-3p ASO represents a potential therapeutic candidate for managing AD pathology and cognitive decline.
Insights
A novel microRNA (miR-485-3p) is elevated in Alzheimer's disease (AD). Targeting it with an antisense oligonucleotide (ASO) reduced AD pathology and improved cognition in mice, offering a potential new therapy.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder with limited therapeutic options.
- Current treatments for AD do not halt disease progression, necessitating novel therapeutic strategies.
- MicroRNAs (miRNAs) play critical roles in regulating gene expression and are implicated in various diseases, including AD.
Purpose of the Study:
- To investigate the role of microRNA-485-3p (miR-485-3p) in Alzheimer's disease pathogenesis.
- To evaluate the therapeutic potential of targeting miR-485-3p using an antisense oligonucleotide (ASO) in an AD mouse model.
Main Methods:
- Quantification of miR-485-3p levels in AD patient tissues and biofluids.
- Administration of miR-485-3p ASO in a transgenic mouse model of AD.
- Assessment of Aβ plaque accumulation, tau pathology, neuroinflammation, and cognitive function.
- In vitro and in vivo studies to elucidate the mechanism of Aβ clearance.
Main Results:
- miR-485-3p was significantly overexpressed in AD patient samples.
- miR-485-3p ASO treatment reduced Aβ plaques, tau pathology, and neuroinflammation in AD mice.
- miR-485-3p ASO enhanced Aβ clearance via CD36-mediated phagocytosis.
- Treatment decreased apoptosis, reduced truncated tau levels, and alleviated cognitive deficits.
Conclusions:
- miR-485-3p is a potential biomarker for the inflammatory aspects of AD.
- miR-485-3p ASO demonstrates therapeutic potential for managing AD pathology and cognitive decline.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:22MicroRNAs
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...